Autotaxin-Lysophosphatidic Acid: From Inflammation to Cancer Development

Abstract EN

Lysophosphatidic acid (LPA) is a ubiquitous lysophospholipid and one of the main membrane-derived lipid signaling molecules.

LPA acts as an autocrine/paracrine messenger through at least six G protein-coupled receptors (GPCRs), known as LPA1–6, to induce various cellular processes including wound healing, differentiation, proliferation, migration, and survival.

LPA receptors and autotaxin (ATX), a secreted phosphodiesterase that produces this phospholipid, are overexpressed in many cancers and impact several features of the disease, including cancer-related inflammation, development, and progression.

Many ongoing studies aim to understand ATX-LPA axis signaling in cancer and its potential as a therapeutic target.

In this review, we discuss the evidence linking LPA signaling to cancer-related inflammation and its impact on cancer progression.